

Commercial & Healthcare Exchange PA Criteria

Effective: September 2nd, 2020

Prior Authorization: Zeposia

Products Affected: Zeposia (ozanimod) oral capsules

Medication Description: Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.

Covered Uses: Treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Exclusion Criteria:

1. Patients who in the last 6 months, have experienced a myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart
2. Patients with the presence of Mobitz type II second-degree or third degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker
3. Patients with severe untreated sleep apnea
4. Patients taking a monoamine oxidase (MAO) Inhibitor

Required Medical Information:

1. Diagnosis

Age Restrictions: 18 years of age or older

Prescriber Restrictions: Prescribed by, or in consultation with, a neurologist or a physician who specializes in the treatment of multiple sclerosis.

Coverage Duration: 12 months

Other Criteria:

- A. Patient has a diagnosis of any of the following relapsing forms of Multiple Sclerosis:
 - a. Relapsing-remitting multiple sclerosis; OR
 - b. Active secondary progressive disease; OR
 - c. Clinically isolated syndrome

References:

1. Zeposia [package insert]. Celgene Corporation. Summit, NJ 07901; March 2020.
2. Ozanimod. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. August 2020.
3. Ozanimod. IBM Micromedex® DRUGDEX®. IBM Watson Health, Greenwood Village, Colorado, USA. June 2020.
4. Treatment for MS. Multiple Sclerosis Foundation - Treatment for MS. <https://msfocus.org/Get-Educated/Treatment-for-MS.aspx>. Accessed 13 August 2020.

Policy Revision history

| Rev # | Type of Change | Summary of Change | Sections Affected | Date |
|-------|----------------|-------------------|-------------------|----------|
| 1 | New Policy | New Policy | All | 9/2/2020 |